An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.

BACKGROUND: Autoantibodies to GAD65 (anti-GAD65) are present in the sera of 70-80% of patients with type 1 diabetes (T1D), but antibodies to the structurally similar 67 kDa isoform GAD67 are rare. Antibodies to GAD67 may represent a cross-reactive population of anti-GAD65, but this has not been form...

Full description

Bibliographic Details
Main Authors: Bindu Jayakrishnan, David E Hoke, Christopher G Langendorf, Ashley M Buckle, Merrill J Rowley
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3072979?pdf=render
_version_ 1818966603295883264
author Bindu Jayakrishnan
David E Hoke
Christopher G Langendorf
Ashley M Buckle
Merrill J Rowley
author_facet Bindu Jayakrishnan
David E Hoke
Christopher G Langendorf
Ashley M Buckle
Merrill J Rowley
author_sort Bindu Jayakrishnan
collection DOAJ
description BACKGROUND: Autoantibodies to GAD65 (anti-GAD65) are present in the sera of 70-80% of patients with type 1 diabetes (T1D), but antibodies to the structurally similar 67 kDa isoform GAD67 are rare. Antibodies to GAD67 may represent a cross-reactive population of anti-GAD65, but this has not been formally tested. METHODOLOGY/PRINCIPAL FINDINGS: In this study we examined the frequency, levels and affinity of anti-GAD67 in diabetes sera that contained anti-GAD65, and compared the specificity of GAD65 and GAD67 reactivity. Anti-GAD65 and anti-GAD67 were measured by radioimmunoprecipitation (RIP) using (125)I labeled recombinant GAD65 and GAD67. For each antibody population, the specificity of the binding was measured by incubation with 100-fold excess of unlabeled GAD in homologous and heterologous inhibition assays, and the affinity of binding with GAD65 and GAD67 was measured in selected sera. Sera were also tested for reactivity to GAD65 and GAD67 by immunoblotting. Of the 85 sera that contained antibodies to GAD65, 28 contained anti-GAD67 measured by RIP. Inhibition with unlabeled GAD65 substantially or completely reduced antibody reactivity with both (125)I GAD65 and with (125)I GAD67. In contrast, unlabeled GAD67 reduced autoantibody reactivity with (125)I GAD67 but not with (125)I GAD65. Both populations of antibodies were of high affinity (>10(10) l/mol). CONCLUSIONS: Our findings show that autoantibodies to GAD67 represent a minor population of anti-GAD65 that are reactive with a cross-reactive epitope found also on GAD67. Experimental results confirm that GAD65 is the major autoantigen in T1D, and that GAD67 per se has very low immunogenicity. We discuss our findings in light of the known similarities between the structures of the GAD isoforms, in particular the location of a minor cross-reactive epitope that could be induced by epitope spreading.
first_indexed 2024-12-20T13:35:31Z
format Article
id doaj.art-0a4ddd543c9146349f226f406790a15d
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-20T13:35:31Z
publishDate 2011-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-0a4ddd543c9146349f226f406790a15d2022-12-21T19:38:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0164e1841110.1371/journal.pone.0018411An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.Bindu JayakrishnanDavid E HokeChristopher G LangendorfAshley M BuckleMerrill J RowleyBACKGROUND: Autoantibodies to GAD65 (anti-GAD65) are present in the sera of 70-80% of patients with type 1 diabetes (T1D), but antibodies to the structurally similar 67 kDa isoform GAD67 are rare. Antibodies to GAD67 may represent a cross-reactive population of anti-GAD65, but this has not been formally tested. METHODOLOGY/PRINCIPAL FINDINGS: In this study we examined the frequency, levels and affinity of anti-GAD67 in diabetes sera that contained anti-GAD65, and compared the specificity of GAD65 and GAD67 reactivity. Anti-GAD65 and anti-GAD67 were measured by radioimmunoprecipitation (RIP) using (125)I labeled recombinant GAD65 and GAD67. For each antibody population, the specificity of the binding was measured by incubation with 100-fold excess of unlabeled GAD in homologous and heterologous inhibition assays, and the affinity of binding with GAD65 and GAD67 was measured in selected sera. Sera were also tested for reactivity to GAD65 and GAD67 by immunoblotting. Of the 85 sera that contained antibodies to GAD65, 28 contained anti-GAD67 measured by RIP. Inhibition with unlabeled GAD65 substantially or completely reduced antibody reactivity with both (125)I GAD65 and with (125)I GAD67. In contrast, unlabeled GAD67 reduced autoantibody reactivity with (125)I GAD67 but not with (125)I GAD65. Both populations of antibodies were of high affinity (>10(10) l/mol). CONCLUSIONS: Our findings show that autoantibodies to GAD67 represent a minor population of anti-GAD65 that are reactive with a cross-reactive epitope found also on GAD67. Experimental results confirm that GAD65 is the major autoantigen in T1D, and that GAD67 per se has very low immunogenicity. We discuss our findings in light of the known similarities between the structures of the GAD isoforms, in particular the location of a minor cross-reactive epitope that could be induced by epitope spreading.http://europepmc.org/articles/PMC3072979?pdf=render
spellingShingle Bindu Jayakrishnan
David E Hoke
Christopher G Langendorf
Ashley M Buckle
Merrill J Rowley
An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.
PLoS ONE
title An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.
title_full An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.
title_fullStr An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.
title_full_unstemmed An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.
title_short An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.
title_sort analysis of the cross reactivity of autoantibodies to gad65 and gad67 in diabetes
url http://europepmc.org/articles/PMC3072979?pdf=render
work_keys_str_mv AT bindujayakrishnan ananalysisofthecrossreactivityofautoantibodiestogad65andgad67indiabetes
AT davidehoke ananalysisofthecrossreactivityofautoantibodiestogad65andgad67indiabetes
AT christopherglangendorf ananalysisofthecrossreactivityofautoantibodiestogad65andgad67indiabetes
AT ashleymbuckle ananalysisofthecrossreactivityofautoantibodiestogad65andgad67indiabetes
AT merrilljrowley ananalysisofthecrossreactivityofautoantibodiestogad65andgad67indiabetes
AT bindujayakrishnan analysisofthecrossreactivityofautoantibodiestogad65andgad67indiabetes
AT davidehoke analysisofthecrossreactivityofautoantibodiestogad65andgad67indiabetes
AT christopherglangendorf analysisofthecrossreactivityofautoantibodiestogad65andgad67indiabetes
AT ashleymbuckle analysisofthecrossreactivityofautoantibodiestogad65andgad67indiabetes
AT merrilljrowley analysisofthecrossreactivityofautoantibodiestogad65andgad67indiabetes